What the immune response to the coronavirus says about the prospects for a vaccine.

  title={What the immune response to the coronavirus says about the prospects for a vaccine.},
  author={Heidi Ledford},
Viral immunologists say that results so far have been predictable — here’s why that’s good news. Viral immunologists say that results so far have been predictable — here’s why that’s good news. 

Decorated and Encapsulated: Virus-Like Particles Against Viral Infections

Despite great progress in the field of vaccine development, outbreaks of emerging pathogens and insufficient immunogenicity of some licensed vaccines call for the development of novel technologies in

V483A: an emerging mutation hotspot of SARS-CoV-2

This review compares the wild-type and the V483A mutants to analyze certain factors like the interaction between the virus and host-cell interface, binding affinity, stability, partition energy, hydrophobicity, occurrence rate and transmissibility.

Emerging Patent Landscape for Gene Therapy as a Potential Cure for COVID-19

An analysis of the emerging patent landscape was given on gene therapies for coronavirus under development, highlighting patent applications' basic status, geographical distribution, time-series analysis of new inventors, and ranking of patent applicants.

V483a – an Emerging Mutation Hotspot of Sars-Cov-2

This review has assembled all information, currently available on V483A mutation, and has made a critical analysis based on the perspectives of many researchers all around the world, about infectivity and evasion of the immune system by the virus.

COVID-19 and Future Disease X in Circular Economy Transition: Redesigning Pandemic Preparedness to Prevent a Global Disaster

Evidence provided here indicates that this novel preventive-based and resource-saving preparedness system could contribute to reverse the detrimental impacts of the pandemic on global economy and increase its resilience, and propose a pro-active global eco-social pandemic preparednessSystem.

Experiencia y manejo de la COVID-19 en Lima Norte

This paper shows the experience lived in the Direccion de Redes Integradas de Lima Norte (DIRIS Lima Norte) in the face of the COVID-19 pandemic, where it was tackled ingeniously and boldly, with

Our Identity Remains Marked!

The purpose of this article is to collectively work towards understanding and resolving the COVID-19 pandemic issues based on Messersmith's (2018) song, The authors All Do Better When They All do Better, to understand and overcome the workings of a virus whose Identity [DOES NOT] Remain Marked.

Understanding COVID-19 vaccines and immunity

In this commentary, some of the issues related to the success and failure of COVID-19 vaccines are reviewed, and the theoretical and practical elements on vaccinations and immunity that the dental health care providers have to be knowledgeable, so as to offer advice and guidance to their team, the patients, as well as the public.



Pre-existing immunity to SARS-CoV-2: the knowns and unknowns

The potential implications of T cell reactivity against SARS-CoV-2 in unexposed people, Crotty and Sette discuss, for disease severity, herd immunity and vaccine development.

The time course of the immune response to experimental coronavirus infection of man

A limited investigation of circulating lymphocyte populations showed some lymphocytopenia in infected volunteers and antibody concentrations started to increase 1 week after inoculation and reached a maximum about 1 week later, thereafter antibody titres slowly declined.

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

A range of preexisting memory CD4+ T cells that are cross-reactive with comparable affinity to SARS-CoV-2 and the common cold coronaviruses human coronavirus (HCoV)-OC43, H coV-229E, H CoV-NL63, and HCov-HKU1 are demonstrated.

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein, and SARS-CoV-2-reactive T cells were found in individuals who had recovered from SARS or COVID-19 and in unexposed donors, although with different patterns of immunoreactivity.

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

It is demonstrated that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated with antiviral protective immunity.

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression and the correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored.

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

A cohort of asymptomatic patients infected with SARS-CoV-2 had significantly lower levels of virus-specific IgG antibodies compared to a cohort of age- and sex-matched symptomatic infected patients.

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

It is suggested that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds.

Broadly neutralizing antibodies in HIV-1 treatment and prevention

Although in very early stages, bnAbs capable of neutralizing a broad range of inter- and intraclade HIV-1 isolates have been demonstrated to have potential in treating patients, they are proposed to be advantageous over the latter as far as durability and side effects are concerned.